Data of 66 EGFR mutant NSCLC patients who were included in Guangzhou medical insurance were analyzed.The efficacy and adverse reactions were evaluated.All the patients were followed-up regularly and the cost of the treatment was recorded. Here, EGFR is linked to non-small cell lung carcinoma.